Testing a new drug for moderate to severe hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This trial tests a new drug called Brivekimig for people with moderate to severe hidradenitis suppurativa (HS) who have not gotten enough relief from oral antibiotics. The goal is to see if it can reduce abscesses and inflamed bumps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had HS for at least 6 months.
- You have HS lesions in at least 2 body areas, with at least one area being stage 2 or 3 (Hurley stage).
- Oral antibiotics did not work well enough, or you could not take them due to side effects or other reasons.
- You have at least 5 total abscesses or painful bumps at the start of the study.
- You have no more than 20 draining tunnels at the start of the study.
- You have not had any serious infections, organ transplants, or certain other medical conditions in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This trial tests a new daily pill called zasocitinib for people with moderate to severe hidradenitis suppurativa (HS) who haven't been helped enough by antibiotics. It aims to reduce painful lumps and abscesses.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tests a new oral medication, remibrutinib, in adults with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful lumps and tunnels. The goal is to see how the drug affects the skin tissue and to gather information for future treatments.
This study tests a new drug called LAD328 for hidradenitis suppurativa (HS), a chronic skin condition with painful lumps and abscesses. The trial is looking for adults with moderate-to-severe HS who haven't responded well to antibiotics to see if this new treatment can help reduce symptoms.
This study tests an investigational medication (olatorepatide) given as a shot (under the skin) to see if it can reduce the number of painful bumps in people with moderate-to-severe hidradenitis suppurativa who also have overweight or obesity. Participants will receive either the active drug or a placebo, and all will use standard antiseptic washes.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.